GVHD
Optimizing Pharmacotherapy In Chronic GVHD
Chronic graft-versus-host disease can occur in a multitude of organs, often characterized by fibrosis or ...
JUNE 16, 2025
Steroids Still the Mainstay Treatment for cGVHD
Corticosteroids remain an effective tool for treating chronic graft-versus-host disease, although they are ...
DECEMBER 20, 2024
Long-Term Management of Solid-Organ and Hematopoietic Cell Transplant Recipients
The long-term success of solid-organ transplant recipients greatly hinges on effective maintenance ...
DECEMBER 15, 2024
FDA Approves Niktimvo for Chronic Graft-Versus-Host Disease
The FDA has approved Niktimvo for the treatment of chronic graft-versus-host disease after failure of at least two ...
AUGUST 15, 2024
New Pediatric Indication for Ibrutinib Granted to Treat GVHD
The FDA granted a new indication for Imbruvica for children 12 months of age and older with cGVHD after failure of ...
AUGUST 25, 2022
Jakafi Approved To Treat Chronic GVHD in Adults and Children
The FDA approved ruxolitinib (Jakafi, Incyte) for chronic graft-versus-host disease after failure of one or two ...
OCTOBER 15, 2021
FDA Approves Jakafi to Treat Acute GVHD
The FDA granted a new indication for Jakafi to treat steroid-refractory acute graft-versus-host disease in adults ...
MAY 28, 2019
FDA Approves Imbruvica to Treat Adults With Chronic GVHD
Imbruvica becomes the first and only therapy specifically approved for adults with cGVHD, a serious and ...
AUGUST 7, 2017
